Glutamine in critical illness: the time has come, the time is now.
Glutamine (GLN) has been shown to be a key pharmaconutrient in the body's response to stress and injury. It exerts its protective effects via multiple mechanisms, including direct protection of cells and tissue from injury, attenuation inflammation, and preservation of metabolic function. Data support GLN as an ideal pharmacologic intervention to prevent or treat multiple organ dysfunction syndrome after sepsis or other injuries in the intensive care unit population. A large and growing body of clinical data shows that in well-defined critically ill patient groups GLN can be a life-saving intervention.
Weitzel
Lindsay-Rae B
LR
Department of Anesthesiology, Translational Pharmaconutrition (TPN) Research Laboratories, University of Colorado Denver, Research Complex 2, Box 8602, 12700 East 19th Avenue, Aurora, CO 80045, USA. Lindsay.Weitzel@ucdenver.edu
Wischmeyer
Paul E
PE
D016638:Critical Illness / Q000628:therapy*; D005973:Glutamine / Q000008:administration & dosage*; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy / Q000517:prevention & control; D007333:Insulin Resistance; D007362:Intensive Care Units; D009102:Multiple Organ Failure / Q000517:prevention & control; D010288:Parenteral Nutrition / Q000379:methods; D012307:Risk Factors; D018805:Sepsis / Q000517:prevention & control
D005973:Glutamine